Distribution deal w/Walgreen is a significant tailwind as it will broaden the appeal of probuphine for MD's who would/could not economically manage the inventory, billing, etc.. that being said, this management is long in the tooth, with bungling failures in their resumes and should have gone after this distribution method in 2016 when they had a longer nun-way time to patent expiration.. management is sub-par and the price of the stock reflects this, so does all the modification of term w/Molteni who have gotten huge concessions for a pittance just so TTNP could keep the lights on and pay unearned salaries of far too many people. the perception that management is incompetent and only focused on burning other people's money for decades is a huge headwind for this stock until they can sustain their business from organic growth of meaningful sales ... not rely on printing paper stock certificates and warrants
Upcoming areas of possible news is EMA approval timeline, why has probuphine not yet been approved in the EU?; Knight Therapeutics report of probuphine sales in Canada;... status of 6 month experiment in Probuphine w/dept of correction in Nevada (despite ICER study that opined long acting inject-able MAP has no cost benefit advantage (generic buprenorphine works just as well, despite diversion issues)...any indications of pain management approval... any FDA news of required clinical trials post approval, etc
News 
Market Data 
Discover 
